NCT07424703 Effect of Bright Light Therapy on Idiopathic Scoliosis
| NCT ID | NCT07424703 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Condition | Idiopathic Scoliosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-09-01 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial aims to investigate whether morning bright light therapy can reduce the progression rate of idiopathic scoliosis in children and potentially prevent its de novo development.
Eligibility Criteria
Inclusion Criteria: 1. Age between 10 and 15 years. 2. Classified as evening chronotype based on the reduced Horne-Östberg Morningness-Eveningness Questionnaire (rMEQ), defined as a score \< 12. 3. Has undergone radiographic evaluation (standing full-spine X-ray) for idiopathic scoliosis at the initial clinic visit. 4. Skeletally immature (Risser sign 0-3) with a major Cobb angle \< 40 degrees at baseline. 5. Written informed consent/assent provided by the participant and legal guardian. 6. Willing and able to comply with the study protocol, including device use and scheduled follow-ups. Exclusion Criteria: 1. Plans to relocate outside the study area within the next 24 months. 2. Use of medications that may interfere with circadian rhythm within the past 3 months (e.g., lithium, exogenous melatonin, melatonergic antidepressants). 3. Trans-meridian travel across at least two time zones within the past 3 months or anticipated during the study period. 4. Presence of any eye disease (e.g., glaucoma, retinal disease, macular degeneration) that could be exacerbated by or interfere with light therapy. 5. Clinically diagnosed sleep disorder (e.g., narcolepsy, restless legs syndrome) or prominent medical condition known to interfere with sleep continuity and quality (e.g., moderate-to-severe eczema). 6. Severe chronic health conditions that could confound study outcomes, including but not limited to: * Known syndromic, neuromuscular, or congenital musculoskeletal causes of scoliosis. * History of spine surgery or significant spinal trauma. * Spinal tumor. * Leg length discrepancy \> 20 mm. * Other severe chronic diseases (e.g., poorly controlled diabetes, chronic liver or renal disease, malabsorption syndromes). * Severe obesity (body mass index z-score ≥ 3).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07424703 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 15 Years, studying Idiopathic Scoliosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07424703 currently recruiting?
Yes, NCT07424703 is actively recruiting participants. Contact the research team at Xiangyangwang@wmu.edu.com for enrollment information.
Where is the NCT07424703 trial being conducted?
This trial is being conducted at Zhejiang, China.
Who is sponsoring the NCT07424703 clinical trial?
NCT07424703 is sponsored by Second Affiliated Hospital of Wenzhou Medical University. The trial plans to enroll 120 participants.